Table 3. Adjuvant chemotherapy treatment decisions divided by Nottingham Prognostic Index (NPI) score for patients selected for Oncotype DX (ODX) testing compared to patients not genetically profiled.

*P values relate to Mann-Whitney tests comparing ODX and non-ODX groups; †, data excluded from statistical analysis due to non-positive values in both groups; NPI, Nottingham Prognostic Index; ODX group, patients with cancers that were genetically profiled through Oncotype DX testing; non-ODX group, patients that did not have Oncotype DX testing.

	Multidisciplinary team decision to offer chemotherapy			P-value*
	All patients	ODX group	Non-ODX Group
All patients, N	24/133	18/46	6/87	<0.0001
Patients with excellent NPI (≤2.4), n (%)	1/60 (45.1%)	1/6 (16.7%)	0/54 (0.0%)	0.1000
Patients with good NPI (2.41–3.4), n (%)	7/45 (33.8%)	6/21 (28.6%)	1/24 (4.2%)	0.0389
Patients with moderate NPI (3.41–5.4), n (%)	16/28 (21.1%)	11/19 (57.9%)	5/9 (55.6%)	>0.9999
Patients with poor NPI (≥5.41), n (%)	0/0 (0.0%)	0/0 (0.0%)†	0/0 (0.0%)†